Parkinsonian neurotoxicants impair the anti-inflammatory response induced by IL4 in glial cells: involvement of the CD200-CD200R1 ligand-receptor pair

dc.contributor.authorRabaneda Lombarte, Neus
dc.contributor.authorBlasco Agell, Lucas
dc.contributor.authorSerratosa i Serdà, Joan
dc.contributor.authorFerigle Burgada, Laura
dc.contributor.authorSaura Martí, Josep
dc.contributor.authorSolà i Subirana, Carme
dc.date.accessioned2021-05-13T10:31:46Z
dc.date.available2021-05-13T10:31:46Z
dc.date.issued2020-06-30
dc.date.updated2021-05-13T10:31:46Z
dc.description.abstractExposure to pesticides such as rotenone is a risk factor for Parkinson's disease. Dopaminergic neurons are especially sensitive to the toxicity of compounds that inhibit the mitochondrial respiratory chain such as rotenone and 1-methyl-4-phenylpyridinium (MPP+). However, there is scarce information on their effects on glia. To evaluate whether these neurotoxicants affect the immune response of glia, primary mouse mixed glial and microglial cultures were treated with interleukin (IL) 4 in the absence and presence of MPP+ or rotenone. Using qRTPCR or western blot, we determined the expression of anti-inflammatory markers, the CD200R1 microglial receptor and its ligand CD200, and genes regulating glycolysis and oxidative metabolism. ATP and lactate levels were additionally determined as an index of cell metabolism. Microglial phagocytosis was also evaluated. MPP+ and rotenone clearly abrogated the IL4-induced expression of anti-inflammatory markers in mixed glial cultures. CD200 and CD200R1 expression and microglia phagocytosis were also affected by the neurotoxicants. Changes in the mRNA expression of the molecules regulating glycolysis and oxidative metabolism, as well as in ATP levels and lactate release suggested that metabolic reprogramming in response to MPP+ and rotenone differs between microglial and mixed glial cultures. These findings support the hypothesis that parkinsonian neurotoxicants may impair brain immune response altering glial cell metabolism.
dc.format.extent19 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec710661
dc.identifier.issn2045-2322
dc.identifier.pmid32606391
dc.identifier.urihttps://hdl.handle.net/2445/177260
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41598-020-67649-4
dc.relation.ispartofScientific Reports, 2020, vol. 10, num. 1, p. 10650
dc.relation.urihttps://doi.org/10.1038/s41598-020-67649-4
dc.rightscc-by (c) Rabaneda Lombarte, Neus et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Biomedicina)
dc.subject.classificationMalaltia de Parkinson
dc.subject.classificationNeuròglia
dc.subject.classificationResposta immunitària
dc.subject.otherParkinson's disease
dc.subject.otherNeuroglia
dc.subject.otherImmune response
dc.titleParkinsonian neurotoxicants impair the anti-inflammatory response induced by IL4 in glial cells: involvement of the CD200-CD200R1 ligand-receptor pair
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
710661.pdf
Mida:
3.47 MB
Format:
Adobe Portable Document Format